Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
REPL Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Replimune Group, Inc.NASDAQ: REPL
Common Stock · Q3 FY2026 · quarter ended Dec 2025
Common stock rises 2.6% from a year ago
Common stock stood at $79K at the end of Q3 FY2026, up 2.6% from a year earlier and up 1.3% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +2.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 77K USD
- Year-over-year change
- +26.2%
- 4-year CAGR
- +13.1%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 77K | +26.2% |
| FY2024 | 2024-03-31 | 61K | +7.0% |
| FY2023 | 2023-03-31 | 57K | +21.3% |
| FY2022 | 2022-03-31 | 47K | +0.0% |
| FY2021 | 2021-03-31 | 47K | — |
Common Stock vs competitors
How REPL compares with its peers on the latest reported figures
- REPL's Dec 2025 common stock of $79K is the 5th highest of the 11 companies compared; the peer median is $39.5K.
- Its year-over-year change of +2.6% is the 6th highest of 11, against a peer median of +4.9%.
- Common stock amounts to 0.0% of total assets for REPL, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $636K | +0.8% | +0.9% | 0.3% | |
| Mar 2026 | $385K | +44.7% | -51.3% | 0.2% | |
| Aug 2026 | $109K | +41.6% | +29.5% | 0.0% | |
| Sep 2026 | $106K | +8.2% | +34.0% | 0.0% | |
| Dec 2025 | $79K | +2.6% | +17.9% | 0.0% | |
| Mar 2026 | $60K | +1.7% | +12.6% | 0.0% | |
| Sep 2026 | $19K | +18.8% | +28.6% | 0.0% | |
| Dec 2025 | $5.92K | +0.6% | +2.5% | 0.0% | |
| Mar 2026 | $2K | +100.0% | +26.0% | 0.0% | |
| Mar 2026 | $2K | -93.3% | -56.9% | 0.0% | |
| Mar 2026 | $0 | -100.0% | +3.0% | 0.0% | |
| Peer median (excluding REPL) | $39.5K | +4.9% | +7.8% | 0.0% | |
Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 182.52M | 105.95M | 146.59M | 74.46M | 111.12M |
| Short-term Investments | 293.78M | 289.71M | 436.8M | 346.21M | 372.69M |
| Net Receivables | 2.95M | 3.06M | 2.94M | 4.92M | 3.73M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 6.28M | 8.08M | 0 |
| Total Current Assets | 483.75M | 403.98M | 592.6M | 433.67M | 495.88M |
| Property, Plant & Equipment (Net) | 57.72M | 55.58M | 52.35M | 52.36M | 52.55M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.64M | 1.64M | 1.64M | 1.7M | 2.9M |
| Total Non-current Assets | 59.35M | 57.22M | 53.99M | 54.06M | 55.45M |
| Total Assets | 543.1M | 461.19M | 646.59M | 487.72M | 551.33M |
| Account Payables | 2.36M | 3.73M | 5.36M | 2.58M | 12.46M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.47M | 6.89M | 12.9M | 17.24M | 6.07M |
| Total Current Liabilities | 14.55M | 20.76M | 33.83M | 40.44M | 62.36M |
| Long-term Debt | 0 | 0 | 28.65M | 44.81M | 46.38M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 472K | 786K | 941K |
| Total Non-current Liabilities | 29.82M | 29.21M | 57.47M | 72.78M | 73.12M |
| Total Liabilities | 44.37M | 49.96M | 91.3M | 113.21M | 135.49M |
| Common Stock | 47K | 47K | 57K | 61K | 77K |
| Retained Earnings | (193.17M) | (311.2M) | (485.49M) | (701.28M) | (948.58M) |
| Accumulated OCI | (394K) | (973K) | 5.73M | 4.86M | 5.45M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 498.73M | 411.23M | 555.29M | 374.51M | 415.84M |
| Total Debt | 33.28M | 32.84M | 60.76M | 75.87M | 76.17M |
| Net Debt | (149.24M) | (73.11M) | (85.83M) | 1.41M | (34.95M) |
Replimune Group, Inc.
NASDAQ:REPL
Intrinsic Alpha fair value
Locked
Current Price
$19.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.